Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei

• DOI: 10.1111/ans.18041
• Publication Date: 2022-09-22T16:20:50Z
• Authors: Ruiqing Ma; Dongmei Lu; Shilin Xue; Xiwen Fan; Xichao Zhai; Chong Wang; Hongbin Xu; Shaojun Pang
• Keywords: Pseudomyxoma Peritonei; Hyperthermic Intraperitoneal Chemotherapy

Pseudomyxoma peritonei (PMP) is a clinically malignant tumour syndrome mainly derived from mucin-producing appendiceal tumours. This study aimed to explore the effect of preoperative systemic chemotherapy (PSC) before cytoreductive surgery (CRS) plus hyperthermic intraperitoneal (HIPEC) on safety and postoperative survival in patients with PMP.We performed retrospective analysis including consecutive PMP undergoing primary between January, 2008 December, 2019 Aerospace Center Hospital. The clinical data were compared PSC group non-PSC group.Seven hundred fifty included study. Significant differences found clinicopathological perioperative outcomes independent risk factor serious complications was blood loss >1000 mL (P = 0.026). Shorter median overall (OS) (42 months, 95% CI 31.9-52.1) than that (67 months 44.5-89.5) group. In stratified PCI < 20, CC 0/1 low-grade pathological subtype, OS significantly better (log rank P-values are <0.001, 0.006 respectively). Multivariate showed 0/1, HIPEC, 20 subtype prognostic factors for OS.PSC does not increase major PMP, but it also bring benefits either.